FOLH1 and prostate carcinoma: PSMA is not expressed or low expressed in approximately 5%–10% of prostate cancer patients; prior studies illustrated these portions of patients mainly seen in severely treated patients receiving multiple chemotherapy and androgen deprivation therapy, poorly differentiated tumors with neuroendocrine differentiation, and dedifferentiated adipocytic carcinoma (35, 36).